Anti-VEGF Utilization In US Shows Preference For Bevacizumab

Home
Cataract
Cornea
Glaucoma
Refractive
Retina
Practice Management

Wednesday, January 19, 2011

Comments

Ocular Surgery News

Despite similar safety and efficacy profiles as ranibizumab in recent studies, bevacizumab appears to be the preferred anti-VEGF agent with regard to utilization in the United States, according to one presenter here.

Full Story

Retina Products and Equipment »

What is the treatment for stage I DLK?
1. Steroids
2. Lifting and irrigating under the flap
3. MMC
4. PTK
Check The Answer

PanoCam™ LT Wide-field Digital Imaging System
The PanoCam LT represents the first ... view product
Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Anti-VEGF Utilization In US Shows Preference For Bevacizumab

Comments

Related Categories

Retina Products and Equipment »

Quick Quiz

What is the treatment for stage I DLK?

AdGlare RMR Ad

Featured Products

PanoCam™ LT Wide-field Digital Imaging System

Smartphone-Based Retinal Screening System

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us